"How to manage loss of response to anti-TNF in Crohn's disease?"

Current Drug Targets

Volumn 11, Issue 2, 2010, Pages 152-155

  Reinisch, Walter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; IMMUNOGENICITY; MAINTENANCE THERAPY; MONOTHERAPY; PUVA; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SERUM SICKNESS; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950847387     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010790309894     Document Type: Review

References (24)

1. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549 (Pubitemid 34621118)
2. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885
3. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
4. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-250 (Pubitemid 47080388)
5. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608 (Pubitemid 36204954)
6. Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-1254 (Pubitemid 44512213)
7. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough Serum Infliximab: A Predictive Factor Of Clinical Outcome For Infliximab Therapy In Acute Ulcerative Colitis. Gut 2009; [Epub ahead of print].
8. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-1459 (Pubitemid 34620190)
9. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
10. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-1563 (Pubitemid 28459913)
11. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomised trial. Gastroenterology 2008; 134: 1861-1868
12. Sandborn WJ, Rutgeerts P, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. SONIC: a randomised, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Am J Gastroenterology 2008. Abstract ACG.
13. Sandborn WJ, Colombel JF, Rutgeerts P, Pollack PF, Chao C, Mulani P, et al. Benefits of Dosage Adjustment With Adalimumab in Crohn's Disease: An Analysis of the CHARM Trial. Gastroenterology 2008; 134(4 Suppl 1): A347-8.
14. Schreiber S, Panes J, Mason D, Lichtenstein G, Sandborn W. Sustained efficacy and tolerability of certolizumab pegol over 18 months: Data from PRECiSE 2 and its extension studies (PRECiSE 3 and 4). Am J Gastroentero 2007; Abstract ACG.
15. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007; 26: 1509-1520
16. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomised trial. Ann Intern Med 2007; 146: 829-838
17. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333
18. Ma C, Panaccione R, Heitman S, Devlin SM, Ghosh S, Kaplan GG. Systematic Review: the short- and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther 2009 [Epub ahead of print].
19. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, et al. Influence of Trough Serum Levels and Immunogenicity on Long-Term Outcome of Adalimumab Therapy in Crohn's Disease. Gastroenterology 2009 [Epub ahead of print]
20. Vermeire S, Raedler A, Abreu MT, Fedorak RN, D'Haens G, Sandborn WJ, et al. Assessment of certolizumab pegol in the treatment of Crohn's disease in patients for whom infliximab treatment was not successful: open-label induction results from the WELCOME study. J Crohn's Colitis (Suppl) 2008; 2(1): 4.
21. Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, et al. Efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF. Aliment Pharmacol Ther 2009; [Epub ahead of print].
22. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136: 1182-1197
23. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925
24. Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, et al. Crohn's Disease Photopheresis Study Group. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis 2009; 15(6): 829-836